VEGFA and neoplasm: In animal models, the use of CB2R agonists and mixed CB1R/CB2R agonists, such as WIN-55,212-2, resulted in reduced tumour growth and metastasis, with treated tumours exhibiting increased apoptosis and decreased levels of Vascular Endothelial Growth Factor (VEGF), a key factor in tumour angiogenesis.